Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 22

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 22
---
 breadth of pre-clinical testing and the size or complexity of our clinical trials and drug delivery programs, all of which directly influence cost; |

| ● | Higher than expected costs involved in complying with the regulatory process to get our drug candidates approved, including the number, size, and timing of necessary clinical trials and costs and review of existing clinical and pre-clinical information; |

| ● | Higher than expected costs involved in patenting our technologies and defending them and pursuing our overall intellectual property strategy. |

<div align='center'>9</div>

| ● | Changes in our existing research and development relationships and our ability to efficiently negotiate and enter into new collaboration and partnership agreements. |

| ● | Our ability to establish and maintain current and new research and development and licensing arrangements and terminations of our existing collaboration and licensing arrangements. |

| ● | Faster or slower than expected rate of progress and changes in the scope and the cost of our research and development and clinical trial activities. |

| ● | Higher than expected                                                                                                       
 costs of preparing an application for clinical trials and FDA and similar regulatory authorities’ approvals of our product 
 candidates’ development programs.                                                                                          |

| ● | FDA approval in general. |

| ● | Higher than expected costs to further develop and scale up manufacturing of our therapeutic candidates through CDMOs (Contract Development and Manufacturing Organizations). |

| ● | Competition for our products. |

| ● | Our ability to achieve milestones under licensing arrangements and the costs involved in enforcing or defending patent claims and other intellectual property rights. |

To date, we have financed our operations through
a mix of equity investments from private investors, and we expect to continue to utilize such means of financing for the foreseeable future.
However, additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms, or at
all.

If we raise capital through the sale of equity,
or securities convertible into equity, it will result in dilution to our then existing stockholders, which could be significant depending
on the price at which we may be able to sell our securities.

If we raise additional capital through the incurrence
of indebtedness, we may become subject to covenants restricting our business activities, and holders of debt instruments may have rights
and privileges senior to those of our equity investors. In addition, servicing the interest and principal repayment obligations under
debt facilities could divert funds that would otherwise be available to support research and development or commercialization activities.
Any debt financing that we obtain in the future